March 14-16, 2017 | Boston, MA

 

Lytix Biopharma

Lytix_Biopharma_CMYK

Lytix Biopharma: Program Partner

Lytix Biopharma is a private R&D company focused on developing novel cancer immunotherapies.

The lead project- LTX315 – a first-in-class oncolytic peptide immunotherapy

LTX-315 makes ”cold tumors hot” and responsive to Immune Checkpoint Inhibitors (ICIs) by releasing an extended range of tumor specific antigens

LTX-35 may be an ideal combination partner for ICIs – potential to augment efficacy without adding significant toxicity.

It has demonstrated strong pre-clinical anticancer activity and increased efficacy with ICIs

In an ongoing phase I study LTX-315 has shown clinical evidence of anti-tumor and systemic immune effects.

– Stable disease (irRC response criteria) – in 50% of patients

– Significant infiltration of CD8+ T-cells – 75% of patients